Summary
This narrative review examines the clinical associations between coffee consumption and reduced risk of MASLD progression, integrating evidence across disease stages with mechanistic explanations grounded in coffee's bioactive compounds. The authors contextualise coffee as a readily accessible dietary intervention complementing weight loss and lifestyle modification, the current cornerstones of MASLD management. The review bridges clinical epidemiology with molecular pathways to support coffee's potential role in MASLD prevention and management.
Regional applicability
The findings are internationally applicable, as MASLD is a global health burden and coffee consumption patterns span all developed healthcare systems including the United Kingdom. UK clinicians and patients could consider the evidence when discussing adjunctive dietary strategies alongside standard weight loss and metabolic interventions, though clinical adoption would require integration with local MASLD management guidelines and consideration of individual tolerability.
Key measures
MASLD progression, liver disease outcomes, cardiovascular risk markers, bioactive compound mechanisms
Outcomes reported
The review synthesises clinical evidence for coffee consumption across stages of metabolic dysfunction-associated steatotic liver disease (MASLD) and explores mechanistic pathways of coffee's bioactive compounds in relation to MASLD progression and outcomes.
Supporting research
Primary abstract focuses on actual coffee consumption associations in MASLD and mechanistic pathways of the beverage components.
Limits: Narrative clinical/mechanistic synthesis; associations and component mechanisms do not establish randomised causal benefit or a treatment recommendation.
Topic tags
Dig deeper with Pulse AI.
Ask about this record, its theme or its relevance to UK farming and policy. Pulse AI uses selected catalogue evidence and cites the sources it draws on.